Heart Test Laboratories, Inc.

NasdaqCM HSCS

Heart Test Laboratories, Inc. Gross Profit Margin for the Trailing 12 Months (TTM) ending October 31, 2024: -245.56%

Heart Test Laboratories, Inc. Gross Profit Margin is -245.56% for the Trailing 12 Months (TTM) ending October 31, 2024, a -638.70% change year over year. Gross Profit Ratio is the ratio of gross profit to net sales, indicating the percentage of revenue that exceeds the cost of goods sold and reflects the efficiency of a company in managing its production or procurement and sales.

Heart Test Laboratories, Inc. Gross Profit Margin for the Trailing 12 Months (TTM) ending October 31, 2023 was 45.58%, a 614.42% change year over year.
Heart Test Laboratories, Inc. Gross Profit Margin for the Trailing 12 Months (TTM) ending October 31, 2022 was -8.86%.

Key data

Date	Gross Profit Margin	Operating Income Margin	EBT Margin	Net Income Margin

NasdaqCM: HSCS

Heart Test Laboratories, Inc.

CEO	Mr. Andrew Simpson
IPO Date	June 16, 2022
Location	United States
Headquarters	550 Reserve Street
Employees	15
Sector	Health Care
Industries Medical Instruments Telehealth

Description

Heart Test Laboratories, Inc., a medical technology company, provides cardiovascular diagnostic devices. The company offers MyoVista wavECG, a resting 12-lead electrocardiograph (ECG) to provide diagnostic information related to cardiac dysfunction, as well as conventional 12-lead resting ECG information. It serves clinics, doctor's offices, urgent care centers, and hospitals. The company was incorporated in 2007 and is headquartered in Southlake, Texas.

Key trends

Past 5 years